Skip to main content
Premium Trial:

Request an Annual Quote

Preparing for US Market, MDx Health Files for CLIA Certification

NEW YORK (GenomeWeb News) – MDx Health today announced the signing of a lease agreement for a laboratory and office facilities in Irvine, Calif.

As a result, it has filed for CLIA certification for the 13,448-square-feet US site. It also has filed for CLIA certification for its facility in Liege, Belgium.

The company said it expects to launch its first assay for prostate cancer next year. In conjunction with a ramp-up of its commercialization operations, MDx Health also announced it has hired Miriam Reyes as senior director of laboratory operations and Beth Davis as senior director of managed care.

"Establishing a US infrastructure that includes CLIA certification will allow us to penetrate the US market more efficiently and is key to our long-term business strategy," Jan Groen, CEO of MDx Health, said in a statement.

In April, the company raised about $11.7 million, part of which was targeted to set up a CLIA laboratory and create a sales and marketing team in the US.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.